Biological drugs (bDMARDs) have changed landscape and outcomes in various rheumatic conditions. Increased risk for infections, paradoxical reactions, autoimmunogenicity are widely acknowledged and may be responsible for treatment failure and switching among biologics.

Objective To assess drug-induced autoimmunity (serology, clinical significance) in patients with rheumatoid arthritis (RA) treated with bDMARDs.

Patients and methods Longitudinal observational study in 246 biomaive RA receiving their first bDMARD, anti-tumour necrosis factor (TNF) or non-TNF drugs, according to local treatment guidelines.

Disease activity, therapeutic response and serial autoantibody profiles (antinuclear (ANA), anti-dsDNA) were systematically assessed at baseline and every six months. Prevalence, clinical significance and therapeutic implications of ANA/anti-dsDNA specificities were further analysed (SPSS-19, p<0.05).

Results 214 RA received TNF inhibitors (56 infliximab, 65 adalimumab, 8 golimumab, 18 certolizumab, 67 etanercept) as first bDMARD and 32 different mechanism of action (10 rituximab, 7 abatacept, 15 tocilizumab). Overall, ANA seroconversion was observed in 31.2% cases, while cardiac tamponade in 4 cases; pericardial thickening was reported in 38% SLE. Finally, abnormal systolic pressure in pulmonary artery was found in 24.79% patients.

Conclusion Patients with SLE are at increased risk to develop either clinical or subclinical cardiovascular manifestations as demonstrated by echocardiographic studies. A systematic TTE assessment is routinely recommended for the screening and monitoring of cardiac events.
investigate and visualise characteristic marker prevalence and co-prevalence patterns.

Results Based on the individual marker pattern, patients can often be stratified belonging to different study subgroups. For example, for SLE we show that different reactivity groups exist including patients with different disease activity scores and organ damage patterns.

Conclusions We conclude that the approach of a comprehensive prevalence and signature analysis and a vivid data visualisation is useful for any multiplex omics assay.

**URINARY MARKERS OF INFLAMMATION IN LUPUS NEPHRITIS PATIENTS**

J Kosalka, J Jakiela, J Musial, Jagiellonian University Medical College, Department of Medicine, Krakow, Poland

10.1136/lupus-2018-abstract.69

Objectives Renal involvement is the most important manifestation of systemic lupus erythematosus, but assessing of inflammatory response in kidneys with non-invasive methods is still challenging. In this study we aimed to define markers of active lupus nephritis (LN) using urine immune profiling.

Methods Levels of cytokines (18-plex array) and mRNA expression (40 immune and glomerular injury genes) were measured in urine samples of LN patients with active disease (n=17), during remission (n=16), and in healthy subjects (n=19).

Results Urine levels of CCL2, CCL5, CXCL10 and IL-6 were elevated in active LN as compared to remission (best discrimination for CCL2), and correlated with LN activity. In the active disease, urinary cell transcriptome showed strong upregulation of proinflammatory cytokines (e.g. TNF, CCL2, CCL5, CXCL10), Th1 related genes (e.g. CD3G, CD4, TBX21, IFNG), and markers of glomerular damage (NPHS2 podocin). Active pattern of gene expression was also observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not observed in 5 patients in remission, who had moderately increased urinary leukocyte count, two patients from this group (40%) developed renal exacerbation during following 3 months. Markers of Th17 immune axis (e.g. IL-17A) were not.

Conclusions Active LN patients (also patients at risk of exacerbation) were characterised by marked increase of proinflammatory mediators in the urine. We identified CCL2 chemokine as the most promising marker for monitoring disease flare.

**USE OF INTERFERON ALPHA AND INTERLEUKIN-10 AS CLINICAL ACTIVITY BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS**

E Grau, M Fernandez Mattila, CM Fecund Olmos, E Labrador Sanchez, FM Ortiz Sanjuan, N Fernandez-Ulloa Comella, C Chalmeta Verdejo, K Arevalo Ruales, R Niguezoros Albuixech, J Ivorra Cortes, JJ Fraguio Gil, JM Martinez Cordelat, R Gonzalez Mazario, L Gonzalez Puig, C Alcaraz Escandell, C Najera Herranz, C Carvajal Olmos, V Vicens Bemabe, JE Oller Rodriguez, M de la Rubia Navarro, JA Castellano Cuesta, V Fornez Ferrer, D Heras Marin, JA Roman Ivorra, Rheumatology Department. HUP La Fe, Valencia, Spain; rheumatology Section. Hospital Arnau de Vilanova, Valencia, Spain; Biostatistics Unit. IIS La Fe, Valencia, Spain

10.1136/lupus-2018-abstract.70

Purpose To analyse the association among INF1A, IL10 and BlyS levels and clinical activity in SLE.

**ANTI-C1Q ANTIBODIES IN TURKISH SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS**

S Tekesoglu, D Temiz Karadag, O Ozdemir Isik, A Yazi, C Celte, Kocaeli University, Internal Medicine, Rheumatology Department, Kocaeli, Turkey

10.1136/lupus-2018-abstract.71

Purpose Anti-C1q has been shown to be associated with systemic lupus erythematosus (SLE) and disease activity of lupus nephritis in previous studies. We studied anti-C1q specificity for SLE versus rheumatic disease controls and healthy controls and the association with SLE manifestations in a single centre cross-sectional study.

Methods Demographic, disease information and blood samples were obtained during routine follow-up visits of patients attending Kocaeli University rheumatology outpatient clinic. There were 150 SLE patients (92% female, mean: 46 years). Control group had 85 rheumatoid arthritis patients, 16 health controls and 16 patients with other rheumatic diseases.

Results We observed higher values of IL10, BlyS and INF1A than healthy controls (p<0.001, p=0.005 and p=0.043 respectively), showing an average values in patients of 13.39±27.73 pg/mL INF1A, 9.99±15.84 pg/mL IL10 and 1811.31±1757.81 pg/mL BlyS. The mean clinical activity measured by SLEDAI was 5.91±5.06.

Statistical analysis indicate that INF1A levels are correlated to IL10 levels (p=0.001) and BlyS levels (p=0.034). Due to this finding, we categorised SLE patients by low or high level of the three cytokines: 44 INF1A(+)IL10(+)BlyS(-); 61 INF1A(+)IL10(-)BlyS(+); 5 INF1A(+)IL10(+)BlyS(+); 18 INF1A(-)IL10(+)BlyS(-) and 14 INF1A(-)IL10(-)BlyS(+). There is a high association of increased IL10-INF1A levels and the increased of clinical activity measured by SLEDAI score (p<0.0001), and to a lesser extent with increased IL10-INF1A-BlyS levels. Patients with high IL10-INF1A and IL10-INF1A-BlyS showed a significant rise in C3-C4 consumption (p<0.001 and p=0.001 respectively) and high anti-dsDNA (p=0.001 and p=0.002 respectively). Patients with increased INF1A-BlyS exhibited high anti-dsDNA (p=0.004) and ENA positivity (p<0.001). In addition, patients with increased levels of IL10-INF1A-BlyS showed ANAs (p<0.001) and antiphospholipid autoantibody positivity (p=0.004).

Conclusions The 69% of our SLE patients displayed almost one cytokine increased, being the INF1A the cytokine that mainly is increased. However, increased IL10 levels, irrespective of whether there is also increased levels of BlyS and/or INF1A, is the cytokine which best fits to clinical activity in SLE.